Buy SUPARTZ®
Showing the single result
-


SUPARTZ® (Italian)
$ 319.00 Add To Cart-+Meta Title: Buy SUPARTZ® Products – Premium Quality & Supply | Direct Doctor Supply
Meta Description: Order SUPARTZ® products with high purity standards and reliable availability. Designed for consistent results with clear usage and guidance for licensed practitioners.
Buy SUPARTZ®
SUPARTZ® is an intra-articular sodium hyaluronate viscosupplement indicated for the treatment of pain associated with knee osteoarthritis in patients who have not achieved adequate relief with conservative therapies such as acetaminophen, exercise, or physical therapy. Distributed in the United States by Bioventus, the SUPARTZ® device family, which includes SUPARTZ® and SUPARTZ® FX, represents the same trusted sodium hyaluronate formulation under a single established product line. Licensed healthcare professionals can buy SUPARTZ® online through Direct Doctor Supply, a trusted wholesale supplier serving orthopedic, rheumatology, and sports medicine practices since 2014. Browse the catalog below to compare available products for your clinic.
About SUPARTZ®
SUPARTZ® is a sterile, viscoelastic solution containing highly purified sodium hyaluronate, a naturally occurring polysaccharide component of healthy synovial fluid, indicated for patients with knee osteoarthritis who continue to experience pain despite conservative treatment and simple analgesics [1][4]. The product was originally developed by Seikagaku Corporation, the PMA holder and manufacturer, and is distributed commercially in the United States by Bioventus.
As a Class III medical device, SUPARTZ® supplements the diminished viscoelastic properties of synovial fluid, helping improve joint lubrication and reduce mechanical stress during movement [4]. Supported by randomized controlled trials, systematic reviews, and long-term post-marketing experience, it is one of the longest-established hyaluronic acid viscosupplements used in orthopedic practice. The clinical evidence supports both symptom relief and a favorable safety profile when the product is administered according to approved labeling [1][3].
Who Makes SUPARTZ®? — Bioventus Manufacturer Profile
SUPARTZ® was developed by Seikagaku Corporation, which holds the original FDA Premarket Approval and serves as the manufacturer of record [4]. In the United States, the product is distributed commercially by Bioventus, a medical technology company headquartered in Durham, North Carolina, focused on orthobiologic solutions supporting bone healing, joint preservation, and musculoskeletal care through evidence-based, minimally invasive technologies.
Bioventus’s orthopedic portfolio includes SUPARTZ® FX, DUROLANE®, and GELSYN-3®, reflecting the company’s role as a specialist distributor of clinically validated, regulatory-compliant joint health products.
SUPARTZ® Viscosupplementation — Treatment Areas and Patient Indications
SUPARTZ® is indicated for the treatment of knee osteoarthritis, a medical condition marked by pain in patients who have not responded adequately to acetaminophen, exercise, physical therapy, or other conservative non-pharmacologic measures [1][4]. It is commonly considered before surgical intervention for individuals whose symptoms continue to interfere with daily activities.
Patients suitable for treatment often present with chronic knee pain, joint inflammation, stiffness, and reduced mobility. Symptoms in patients with joint inflammation typically worsen during activities that put stress on the joint, including jogging, tennis, heavy lifting, and standing on your feet for long periods. SUPARTZ® injections for knees help restore the viscoelastic properties of synovial fluid, improving joint lubrication and helping the knee to move more smoothly [1][2].
Although SUPARTZ® is approved specifically for knee osteoarthritis, published literature has explored hyaluronic acid viscosupplementation for selected patients with osteoarthritis of the foot and ankle. These applications remain outside the approved indication and should be guided by physician judgment and current clinical evidence [1].
Because SUPARTZ® is manufactured from avian-derived sodium hyaluronate, patients with hypersensitivity to avian proteins, feathers, or egg products are contraindicated for treatment. Injection should also be postponed in the presence of active infection or skin disease at the intended injection site [1][4].
The Science Behind SUPARTZ® — Sodium Hyaluronate and Synovial Fluid
Healthy synovial fluid contains hyaluronic acid, a naturally occurring polysaccharide that functions as a lubricant and shock absorber within the joint, protecting cartilage surfaces during movement. In osteoarthritis, both the concentration and quality of endogenous hyaluronic acid decline, reducing the fluid’s ability to protect cartilage and contributing to pain, stiffness, and decreased mobility [1][2].
SUPARTZ® contains 25 mg of highly purified sodium hyaluronate in a 2.5 mL prefilled syringe (10 mg/mL), with a molecular weight of approximately 620 to 1,170 kDa [1][4]. Following intra-articular administration, it supplements depleted synovial fluid by restoring viscoelastic characteristics and improving lubrication while supporting the joint’s normal biomechanical function [1][2]. This is the core mechanism of action for SUPARTZ®: it works as a shock absorber in the joint rather than as a drug. Beyond immediate mechanical effects, research also suggests that exogenous hyaluronic acid may influence inflammatory pathways, modulate pain signaling, and stimulate endogenous hyaluronan production within the joint [2]. These wider mechanisms of action remain an active area of study.
SUPARTZ® Product Range
The SUPARTZ® device family provides a focused sodium hyaluronate viscosupplement option for managing symptomatic knee osteoarthritis, with the active formulation and mechanism of action consistent across the product line [1][4].
The original SUPARTZ® regimen was developed around a five-injection weekly protocol supported by pivotal clinical studies. SUPARTZ® FX is the current market iteration of the same formulation. Its labeling sets a flexible three-to-five injection course, with five weekly injections as the standard and a three-injection schedule permitted where the physician judges the patient will benefit [1].
The practical difference between SUPARTZ® and SUPARTZ® FX therefore sits in schedule flexibility rather than active substance. Clinics looking to order SUPARTZ® can confirm current product availability and applicable labeling with Direct Doctor Supply support staff.
Most Popular SUPARTZ® Products
SUPARTZ® Joint Fluid Therapy (2.5 mL Prefilled Syringe)
SUPARTZ® Joint Fluid Therapy contains 25 mg of sodium hyaluronate in a 2.5 mL prefilled syringe, administered as a course of five weekly intra-articular injections for knee osteoarthritis. Its long clinical history and consistent performance across randomized controlled trials have established it as a trusted viscosupplementation option for improving joint function and relieving osteoarthritic knee pain [1][3].
SUPARTZ® FX (2.5 mL Prefilled Syringe)
SUPARTZ® FX carries the same purified sodium hyaluronate active substance and mechanism of action as the original, differentiated primarily by its dosing flexibility. Clinical labeling indicates some patients may experience therapeutic benefit with a three-injection course, while the standard approved schedule remains five weekly injections [1][4]. Practitioners should refer to the current IFU for the applicable dosing protocol.
How SUPARTZ® Injections Are Administered
SUPARTZ® is administered by intra-articular injection directly into the affected knee joint using aseptic technique, performed by a qualified healthcare professional experienced in joint injection procedures and in accordance with approved product labeling [1][4]. Where within scope of practice, intra-articular injections may be performed by nurse practitioners, subject to regional scope-of-practice laws and institutional policies.
The standard approved treatment course is five consecutive weekly injections, and clinical labeling indicates that some patients may achieve therapeutic benefit with a shorter three-injection course [1]. Patients should complete the prescribed series of SUPARTZ® shots to achieve the intended therapeutic benefit. Following each injection, patients should avoid strenuous activities such as jogging, tennis, heavy lifting, or prolonged weight-bearing for approximately 48 hours [1][4].
Symptom improvement from a course of SUPARTZ® shots is typically gradual, with many patients reporting reduced pain and improved mobility over several weeks [1]. Clinical studies indicate that the benefits of a completed SUPARTZ® injection series may last for up to six months in appropriate candidates, though outcomes vary by disease severity and individual factors [1][3].
Why Healthcare Professionals Choose SUPARTZ® Over Competing Viscosupplements
SUPARTZ® has been evaluated in numerous randomized controlled trials and systematic reviews, providing practitioners with a substantial foundation for treatment decisions and repeat injection courses [1][2][3]. This depth of evidence also supports established reimbursement pathways. SUPARTZ®’s longstanding use in orthopedic practice means many payers are already familiar with documentation requirements, which helps streamline administrative processes when viscosupplementation is clinically appropriate [5]. Practices sourcing across musculoskeletal treatment categories can also buy orthopedic injections through Direct Doctor Supply alongside their SUPARTZ® orders.
Because SUPARTZ® and SUPARTZ® FX share the same sodium hyaluronate formulation and mechanism of action, practitioners work within a single, well-characterized product family when managing patients across different treatment schedules [1][4]. This supports consistent clinical decision-making without introducing a different active substance or delivery technology.
SUPARTZ® Alternatives — How It Compares to Other Viscosupplements
HYALGAN® vs SUPARTZ®
HYALGAN® and SUPARTZ® are both avian-derived sodium hyaluronate viscosupplements administered as multi-injection treatment courses. Their mechanisms are similar, so the hyalgan vs supartz decision usually comes down to injection protocols, product characteristics, and reimbursement considerations for specific patient populations. Clinicians comparing those factors can buy HYALGAN® and run it against SUPARTZ® in their own patient population.
SYNVISC® vs SUPARTZ®
SYNVISC® contains cross-linked hylan G-F 20, while SUPARTZ® uses non-cross-linked purified sodium hyaluronate. That structural distinction affects rheological properties and tolerability profiles. Both are avian-derived, but the cross-linked versus non-cross-linked difference may influence clinical choice, and practices can buy SYNVISC® through the same Direct Doctor Supply catalog.
ORTHOVISC® vs SUPARTZ®
ORTHOVISC® is manufactured using non-avian, bacterially fermented sodium hyaluronate with an ultra-high molecular weight range, distinguishing it from SUPARTZ®’s avian-derived, lower molecular weight profile. For practitioners treating patients with avian sensitivities, the option to buy ORTHOVISC® provides a non-avian comparator to evaluate alongside SUPARTZ® before making a formulary decision.
EUFLEXXA® vs SUPARTZ®
EUFLEXXA® is produced through bacterial fermentation rather than avian extraction, giving it a non-avian HA profile that removes the avian allergy contraindication associated with SUPARTZ®. Both products restore synovial fluid viscosity but differ in source material and molecular weight. Practices ready to buy EUFLEXXA® will find it in the same catalog as SUPARTZ® for straightforward side-by-side ordering.
MONOVISC® vs SUPARTZ®
MONOVISC® is a single-injection viscosupplement, while SUPARTZ® is administered as a multi-injection weekly course. The choice between the two often reflects patient preference for visit frequency and clinic scheduling protocols. Practices looking to offer both treatment formats to their patient population can buy MONOVISC® through Direct Doctor Supply.
SUPARTZ® Safety and Side Effects
SUPARTZ® has a well-established safety profile supported by clinical trials and long-term post-marketing experience. Evidence from systematic reviews indicates that repeated treatment courses do not appear to increase the frequency or severity of adverse events compared with the initial series when administered according to approved labeling [3].
The most common side effects of SUPARTZ® injections are localized reactions at the injection site, including:
- Temporary pain
- Swelling
- Warmth
- Redness
- Discomfort at the injection site
Other reported SUPARTZ® injection side effects include transient arthralgia, headache, or back pain, which generally resolve without intervention [1][3]. Hypertension is not listed among the expected or common adverse reactions in the approved prescribing information or published safety data [1][4]. Patients with existing cardiovascular conditions should continue routine management under their treating physician.
SUPARTZ® Licensing, Regulatory Status, and Insurance Coverage
SUPARTZ® received FDA Premarket Approval (PMA P980044) as a Class III medical device for the treatment of pain associated with knee osteoarthritis in patients who have not responded adequately to conservative therapy and simple analgesics [4]. It is approved for intra-articular administration in the United States and continues to be monitored through post-market regulatory oversight. Outside the United States, SUPARTZ® and related sodium hyaluronate products have been marketed under regional regulatory frameworks. Healthcare professionals should consult the prescribing information applicable to their local market before use.
Medicare coverage and reimbursement may be available when specific Local Coverage Determination (LCD) criteria and medical necessity requirements are met [5]. Documentation typically includes confirmed knee osteoarthritis, persistent symptoms despite conservative management, and clinical justification for treatment. Providers should verify individual patient eligibility and consult their MAC’s current LCD before treatment, as regional requirements vary [5].
Many commercial health plans also cover viscosupplementation in appropriately selected patients, though prior authorization requirements, reimbursement policies, and any patient-facing SUPARTZ® injection cost differ between insurers. Providers should verify individual payer criteria prior to treatment [5].
SUPARTZ® Distribution and Market Reach
SUPARTZ® is distributed through authorized medical device suppliers serving orthopedic, rheumatology, rehabilitation, and sports medicine practices. Its long clinical history and continued availability have maintained it as a widely recognized option for non-surgical management of symptomatic knee osteoarthritis [1].
Licensed healthcare professionals can buy SUPARTZ® wholesale through Direct Doctor Supply, which has supplied medical practices with reliable product sourcing, competitive pricing, dependable shipping, and dedicated support staff since 2014. When buying online through Direct Doctor Supply, practitioners benefit from a streamlined ordering process designed for licensed clinical procurement. To purchase SUPARTZ® online or check for wholesale buying options, browse the catalog above or contact the Direct Doctor Supply support team directly.
Clinics offering both orthopedic and aesthetic services can buy hyaluronic acid dermal fillers through Direct Doctor Supply alongside their orthopedic orders. Practices looking to expand their aesthetic offering can also buy dermal fillers from the same professional wholesale platform, consolidating procurement across specialties.
Buy SUPARTZ® Wholesale Through Direct Doctor Supply
Direct Doctor Supply supplies SUPARTZ® to qualified, licensed practitioners and clinic procurement teams only. Before you buy SUPARTZ® online, sourcing from a supplier with verifiable purity documentation, LOT number traceability, and a certificate of analysis protects both patient safety and regulatory standing. Direct Doctor Supply maintains an orthopedic injectables catalog with competitive wholesale pricing and temperature-appropriate shipping to preserve product integrity in transit.
To buy SUPARTZ® wholesale for recurring supply, or to confirm current availability and lead times, reach out to the Direct Doctor Supply support team.
Frequently Asked Questions
What is SUPARTZ® made of?
SUPARTZ® contains highly purified sodium hyaluronate derived from rooster combs, supplied as a sterile solution for intra-articular injection [1][4]. It is not a corticosteroid.
Is SUPARTZ® a steroid?
No. SUPARTZ® is a sodium hyaluronate viscosupplement and does not contain corticosteroids [1][4]. It acts locally within the knee joint to restore synovial fluid viscoelasticity through mechanical and biological mechanisms rather than pharmacological anti-inflammatory pathways.
What is SUPARTZ® used for?
SUPARTZ® is indicated for the treatment of pain associated with knee osteoarthritis in patients who have not responded adequately to conservative therapies such as acetaminophen, exercise, or physical therapy [1][4]. It supplements synovial fluid to improve joint lubrication and support smoother movement.
How does SUPARTZ® work?
SUPARTZ® restores the viscoelastic properties of synovial fluid using purified sodium hyaluronate, helping reduce friction within the knee joint and supporting normal biomechanical function [1][2]. Research also suggests it may influence pain pathways and stimulate endogenous hyaluronan production [2].
What is the difference between SUPARTZ® and SUPARTZ® FX?
SUPARTZ® and SUPARTZ® FX represent the same sodium hyaluronate formulation within the same device family, differing mainly in dosing schedule flexibility [1][4]. Consult current product labeling for the specific dosing protocol applicable to your market.
How long does it take for SUPARTZ® injections to work?
Symptom improvement is typically gradual, with many patients reporting reduced pain and improved mobility over several weeks following the start of treatment [1]. Individual response varies by disease severity and patient-specific factors.
How long do SUPARTZ® injections last?
Clinical studies indicate that symptom relief may last for up to six months following a completed treatment course [1][3]. Individual outcomes vary.
Does Medicare cover SUPARTZ® injections?
Medicare coverage may be available when specific Local Coverage Determination criteria and medical necessity requirements are met [5]. Providers should verify individual patient eligibility and consult their MAC’s current policy before treatment.
Can a nurse practitioner inject SUPARTZ®?
In most settings, a nurse practitioner can inject SUPARTZ® where permitted by regional scope-of-practice laws and institutional policies. Healthcare providers should confirm applicable licensing requirements before administering treatment.
Can SUPARTZ® cause hypertension?
Hypertension does not appear among the expected or common adverse reactions in the approved prescribing information or published safety data for these knee shots [1][4]. Patients with cardiovascular conditions should continue routine management under their treating physician.
What are the side effects of SUPARTZ® injections?
The most commonly reported adverse reactions include temporary pain, swelling, warmth, redness, and discomfort at the injection site [1][3]. Serious adverse events are uncommon when the product is used according to approved labeling.
Looking to buy SUPARTZ® products?
Direct Doctor Supply has stocked SUPARTZ® for licensed practitioners and clinic procurement teams since 2014. Competitive wholesale pricing, dedicated support staff, and guaranteed delivery are available for both individual and bulk orders. To place an order, browse the catalog above or contact the Direct Doctor Supply support team, whether you purchase online for a single clinic or order wholesale for recurring supply.
Citations and Resources about SUPARTZ®
[1] Bronstone A, Neary JT, Lambert TH, Dasa V. Supartz (sodium hyaluronate) for the treatment of knee osteoarthritis: a review of efficacy and safety. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2019;12:1179544119835221. https://pmc.ncbi.nlm.nih.gov/articles/PMC6463231/
[2] Altman RD, Dasa V, Takeuchi J. Review of the mechanism of action for Supartz FX in knee osteoarthritis. Cartilage. 2018;9(1):11-20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5724672/
[3] Bannuru RR, Brodie CR, Sullivan MC, McAlindon TE. Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Cartilage. 2016;7(4):322-332. https://pubmed.ncbi.nlm.nih.gov/27688841/
[4] U.S. Food and Drug Administration. Premarket Approval (PMA) P980044 — SUPARTZ FX. FDA. Updated 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980044
[5] Centers for Medicare & Medicaid Services. LCD — Hyaluronic Acid Injections for Knee Osteoarthritis (L39260). 2022. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39260&keyword=hyalur&bc=0
All content on this website is intended for informational purposes and does not constitute medical advice.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.